Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix to Present Corporate Overview at the Oppenheimer & Co. 25th Annual Healthcare Conference
Rehovot, Israel and Bridgewater, NJ – December 5, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2014
Rehovot, Israel – November 14, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announces financial results for
Toggle Summary Foamix Announces Two New U.S. Patents Relating to Topical Tetracycline Compositions
New Patents Provide Additional Coverage for Lead Product Candidates FMX101, FMX102, and FDX104   Rehovot, Israel and Bridgewater, NJ – November 13, 2014 – Foamix Pharmaceuticals Ltd. (“Foamix Pharmaceuticals”), a clinical-stage, specialty pharmaceutical company focused on developing and
Toggle Summary Foamix Pharmaceuticals Third Quarter 2014 Conference Call & Webcast Scheduled for Monday, November 17, 2014
Rehovot, Israel, and Bridgewater, NJ – November 10, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals to Host Key Opinion Leader Meeting and Webcast on November 4th in New York City
Rehovot, Israel, and Bridgewater, NJ - October 29, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Initiation of Phase II Trial with FDX104 in Chemotherapy Induced Rash
Rehovot, Israel, and Bridgewater, NJ –    October 6, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”, or “Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Pharmaceuticals Ltd. Announces Closing of Initial Public Offering
REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 23, 2014 (GLOBE NEWSWIRE) --    Foamix Pharmaceuticals Ltd. ( FOMX ), ("Foamix Pharmaceuticals" or "Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address
Toggle Summary Foamix Pharmaceuticals Ltd. Prices Initial Public Offering
REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 18, 2014 (GLOBE NEWSWIRE) --   Foamix Pharmaceuticals Ltd. ("Foamix Pharmaceuticals", or "Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in